IBA Adds AI Quality Assurance via PhantomX Acquisition
Dosimetry portfolio strengthened with Medical Imaging QA and AI validation
IBA (Ion Beam Applications S.A., EURONEXT), the world chief in particle accelerator know-how and a world-leading supplier of high quality assurance (QA) options, at present publicizes the acquisition of PhantomX GmbH, increasing IBA’s portfolio in healthcare diagnostics and therapeutic methods enabling synthetic intelligence (AI) high quality assurance.
Founded in 2018 by Dr. Paul Jahnke and Dr. Felix Schwarz, with help from Charité University Hospital in Berlin, PhantomX is a acknowledged chief within the improvement of practical anthropomorphic phantoms. The firm’s proprietary superior high quality assurance applied sciences are used globally for validating diagnostic and therapeutic imaging methods, in addition to medical schooling and coaching. PhantomX is on the forefront of high quality assurance for AI functions in medical imaging and supplies instruments for AI-enhanced scientific options.
“PhantomX’s experience in AI validation completely enhances IBA’s portfolio of Clinical Workflow Solutions in Radiation Therapy and Medical Imaging,” stated Jean-Marc Bothy, President of IBA Dosimetry. “Together, we’ll speed up innovation in our Medical Imaging Business Line with simulation and AI-driven applied sciences, delivering larger worth to clinicians and sufferers worldwide.”
Dr. Paul Jahnke, one of many Founders of PhantomX, added: “This merger empowers us to deliver our know-how to new markets and contribute to the way forward for clever, secure, and efficient medical options.”
The publish IBA Adds AI Quality Assurance via PhantomX Acquisition first appeared on AI-Tech Park.
